S&P Futures
4,249.75 -15.00 (-0.35%) Dow Futures
33,101.00 -100.00 (-0.30%) Nasdaq Futures
14,660.25 -54.25 (-0.37%) Russell 2000 Futures
1,733.30 -8.60 (-0.49%) Crude Oil
89.15 -0.08 (-0.09%) Gold
1,835.90 -5.60 (-0.30%)
Axcella Health Inc. (AXLA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 10.42 |
| Open | 10.06 |
| Bid | 10.27 x 900 |
| Ask | 10.98 x 1200 |
| Day's Range | 10.06 - 11.00 |
| 52 Week Range | 2.59 - 47.75 |
| Volume | |
| Avg. Volume | 956,948 |
| Market Cap | 31.393M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -18.22 |
| Earnings Date | Oct 30, 2023 - Nov 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 192.66 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AXLA
Related Research
- Axcella Health Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat6 days agoMorningstar
InvestorPlaceBeware! 3 Biotech Stocks Waving Massive Red Flags Right Now
The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive. Therefore, it is extraordinarily common to find heavily indebted firms that incur massive losses when investing in the sector. That’s essentially the MO for all of the biotechnology industry: Spend a lot of money for a chance at even greater sums of money and hope you don’t flame out. The numbers don’t lie, though, and
ZacksAre Medical Stocks Lagging Axcella Health (AXLA) This Year?
Here is how Axcella Health Inc. (AXLA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Business WireAxcella Announces Reverse Stock Split Effective September 19, 2023
CAMBRIDGE, Mass., September 14, 2023--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The
